Anna Roberto1, Silvia Deandrea2, Maria Teresa Greco3, Oscar Corli1, Eva Negri4, Massimo Pizzuto5, Fabrizio Ruggeri6. 1. Pain and Palliative Care Research Unit, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy. 2. Institute for Health and Consumer Protection, DG Joint Research Centre, European Commission, Ispra, Italy. 3. Pain and Palliative Care Research Unit, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unità di Statistica Medica e Biometria "G. A. Maccacaro", Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy. Electronic address: mtgrc@yahoo.it. 4. Department of Epidemiology, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy. 5. Palliative Care and Pain Therapy Unit, Istituti Clinici di Perfezionamento Hospital, Milan, Italy. 6. Consiglio Nazionale delle Ricerche, Istituto di Matematica Applicata e Tecnologie Informatiche, Milan, Italy.
Abstract
CONTEXT: Because of the increasing body of literature on neuropathic cancer pain (NCP), an accurate estimate of its prevalence requires recurring updates. OBJECTIVES: To provide this estimate using information from a systematic review and a survey. METHODS: Using MEDLINE, Embase, and a previous review, we searched for studies published up to 2014 reporting data on NCP prevalence in adult cancer populations. Pooled prevalence rates from observational prospective studies were computed. The association between NCP prevalence and possible predictors was investigated for oncology and palliative settings. Prevalence rates were extracted from a questionnaire answered by 137 physicians working in 50 Italian centers of palliative care. Estimates from studies conducted in palliative settings and from the experts were analyzed separately and eventually pooled with an informative Bayesian random-effect model. RESULTS: Twenty-nine observational studies were identified. The overall pooled prevalence was 31.2%, with high heterogeneity; similar figures were observed when oncology and palliative settings were individually considered. A slightly higher prevalence of NCP was detected for hospice/inpatients as compared to outpatients, in both settings. The mean NCP prevalence reported by the survey experts was 44.2%; the pooled Bayesian estimate for the palliative setting corresponded to 43.0% (95% CI: 40.0-46.0). The subgroup with the lowest heterogeneity and where the literature and experts' estimates were closest is hospice/inpatients, with a pooled Bayesian prevalence rate of 34.9% (95% CI: 29.9-41.0). CONCLUSION: The systematic review and the survey suggest that more than one in three patients with cancer pain also experiences NCP.
CONTEXT: Because of the increasing body of literature on neuropathic cancer pain (NCP), an accurate estimate of its prevalence requires recurring updates. OBJECTIVES: To provide this estimate using information from a systematic review and a survey. METHODS: Using MEDLINE, Embase, and a previous review, we searched for studies published up to 2014 reporting data on NCP prevalence in adult cancer populations. Pooled prevalence rates from observational prospective studies were computed. The association between NCP prevalence and possible predictors was investigated for oncology and palliative settings. Prevalence rates were extracted from a questionnaire answered by 137 physicians working in 50 Italian centers of palliative care. Estimates from studies conducted in palliative settings and from the experts were analyzed separately and eventually pooled with an informative Bayesian random-effect model. RESULTS: Twenty-nine observational studies were identified. The overall pooled prevalence was 31.2%, with high heterogeneity; similar figures were observed when oncology and palliative settings were individually considered. A slightly higher prevalence of NCP was detected for hospice/inpatients as compared to outpatients, in both settings. The mean NCP prevalence reported by the survey experts was 44.2%; the pooled Bayesian estimate for the palliative setting corresponded to 43.0% (95% CI: 40.0-46.0). The subgroup with the lowest heterogeneity and where the literature and experts' estimates were closest is hospice/inpatients, with a pooled Bayesian prevalence rate of 34.9% (95% CI: 29.9-41.0). CONCLUSION: The systematic review and the survey suggest that more than one in three patients with cancer pain also experiences NCP.
Authors: C Jara; S Del Barco; C Grávalos; S Hoyos; B Hernández; M Muñoz; T Quintanar; J A Meana; C Rodriguez; R de Las Peñas Journal: Clin Transl Oncol Date: 2017-11-10 Impact factor: 3.405
Authors: Viveka Andersson; Stefan Bergman; Ingela Henoch; Hanna Simonsson; Karin Ahlberg Journal: Support Care Cancer Date: 2019-12-10 Impact factor: 3.603
Authors: Markus S Anker; Sara Hadzibegovic; Alessia Lena; Yury Belenkov; Jutta Bergler-Klein; Rudolf A de Boer; Dimitrios Farmakis; Stephan von Haehling; Zaza Iakobishvili; Christoph Maack; Radek Pudil; Hadi Skouri; Alain Cohen-Solal; Carlo G Tocchetti; Andrew J S Coats; Petar M Seferović; Alexander R Lyon Journal: ESC Heart Fail Date: 2019-12-28